Antithrombin-lowering in hemophilia: a closer look at fitusiran

A Molecular Revolution in the Treatment of Hemophilia: Molecular Therapy

Fitusiran Emerges as a Potential Pan-Hemophilia Rebalancing Agent

Fitusiran Prevents Bleeds in Hemophilia A or B Over Long Term, Study Finds

A Molecular Revolution in the Treatment of Hemophilia. - Abstract - Europe PMC

RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A: Molecular Therapy - Nucleic Acids

Gene therapy in haemophilia: literature review and regional perspectives for Turkey - Kaan Kavaklı, Bülent Antmen, Vahap Okan, Fahri Şahin, Selin Aytaç, Can Balkan, Ergül Berber, Zühre Kaya, Alphan Küpesiz, Bülent Zülfikar

Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect

Fitusiran update following EAHAD 2021 Congress – WFH - World Federation of Hemophilia

Hemophilia A (Factor VIII Deficiency): Practice Essentials, Background, Pathophysiology

Non‐factor therapies for bleeding disorders: A primer for the general haematologist - Swan - 2022 - eJHaem - Wiley Online Library

IJMS, Free Full-Text

Full article: Current and emerging biologics for the treatment of hemophilia

Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A

Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect